Kevin Charles Gorman Sells 2,707 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) CEO Kevin Charles Gorman sold 2,707 shares of the firm’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $140.69, for a total value of $380,847.83. Following the transaction, the chief executive officer now owns 502,188 shares of the […]

Related Keywords

Tokio ,Tokyo ,Japan ,Canada ,Neurocrine Biosciences ,Kevin Charles Gorman ,Securities Exchange Commission ,Linden Thomas Advisory Services ,Neurocrine Biosciences Company Profile ,Larson Financial Group ,Royal Bank ,Truist Financial Corp ,Neurocrine Biosciences Inc ,Cantor Fitzgerald ,Deutsche Bank Aktiengesellschaft ,Nasdaq ,Tokio Marine Asset Management Co ,Barclays ,Get Free Report ,Charles Gorman ,Exchange Commission ,Biosciences Stock Down ,Financial Corp ,Marine Asset Management ,Thomas Advisory Services ,Financial Group ,Bank Aktiengesellschaft ,Neurocrine Biosciences Daily ,Nasdaq Nbix ,Nbix ,Medical ,64125c10 ,Insider Trading ,Nsider Trades ,Stocks ,